NGL Fine-Chem Ltd. (NGLFINE) AI Stock Analysis

• Market Cap: ₹8.27B
• Dividend Yield: 0.14%
• Average Volume (3M): 613.00
• Price to Earnings (P/E): 39.6
• Beta (1Y): 0.78
• Revenue Growth: 6.44%
• EPS Growth: -50.37%
• Country: IN
• Employees: 682
• Sector: Basic Materials
• Sector Strength: 60
• Industry: Drug Manufacturers - General
• EPS (TTM): 14.96
• Shares Outstanding: 6,178,024
• 10 Day Avg. Volume: 390
• 30 Day Avg. Volume: 613
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,439.00
• Price Target Upside: 8.97% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: ₹1,439.00 ▲(8.97% Upside)

NGL Fine-Chem Ltd. has a solid growth trajectory with strong revenue and equity growth, but faces challenges in profitability and cash flow management. The stock shows positive technical momentum, but its high valuation and low dividend yield are concerns for value-focused investors.

NGL Fine-Chem Ltd. Business Overview & Revenue Model

Company Description

NGL Fine-Chem Ltd. (NGLFINE) is a pharmaceutical company based in India that specializes in the manufacture of veterinary pharmaceuticals and active pharmaceutical ingredients (APIs). The company operates in the healthcare sector, focusing on producing high-quality veterinary products to meet the demands of the global animal health industry. NGL Fine-Chem Ltd. is committed to maintaining stringent quality standards and regulatory compliance, ensuring its products are safe and effective for animal use.

How the Company Makes Money

NGL Fine-Chem Ltd. generates revenue primarily through the sale of its veterinary pharmaceutical products and active pharmaceutical ingredients (APIs). The company supplies these products to both domestic and international markets, serving various clients in the animal healthcare industry. By focusing on niche markets within the veterinary sector, NGL Fine-Chem Ltd. capitalizes on its expertise in developing and producing specialized pharmaceuticals that cater to specific needs. Additionally, the company may engage in strategic partnerships and collaborations to enhance its product offerings and expand its market reach, though specific partnerships are not detailed here. The company's earnings are influenced by factors such as product demand, pricing strategies, and compliance with regulatory standards worldwide.

NGL Fine-Chem Ltd. Financial Statement Overview

Summary

NGL Fine-Chem Ltd. shows strong revenue growth and a stable equity position, which are vital for long-term sustainability. However, profitability challenges due to fluctuating margins and increasing leverage pose potential risks. The company's cash flow management also needs improvement, as evidenced by negative Free Cash Flow and inefficiencies in converting profits into free cash flow.

Income Statement

NGL Fine-Chem Ltd. has demonstrated robust revenue growth over the years, with a significant increase in Total Revenue from 2020 to 2025. The Gross Profit Margin and Net Profit Margin have shown variability, reflecting fluctuations in cost management and profitability. Although the recent year saw a decline in Net Income, the company's EBIT Margin and EBITDA Margin, while varying, indicate a stable operational performance. Overall, the income statement suggests a growing company with solid revenue but facing profitability challenges in recent years.

Balance Sheet

The balance sheet of NGL Fine-Chem Ltd. reflects a stable equity base with Stockholders' Equity consistently increasing. However, the Debt-to-Equity Ratio has risen recently, indicating increased leverage. The Equity Ratio remains healthy, suggesting a strong equity foundation. Return on Equity (ROE) has been inconsistent, indicating variable profitability relative to shareholders' investments. Overall, the balance sheet shows strengths in equity growth but reveals potential risks due to increasing leverage.

Cash Flow

The cash flow analysis reveals challenges in generating free cash flow, as evidenced by negative Free Cash Flow in recent periods. Operating Cash Flow has seen growth but not at a pace to offset high capital expenditures. The Free Cash Flow to Net Income Ratio indicates inefficiencies in converting profits into free cash flow. Overall, the cash flow statement highlights a need for improved cash management and cost control measures.

Breakdown	Mar 2025	Mar 2023	Mar 2024	Mar 2022	Mar 2021
Income Statement
Total Revenue	3.68B	2.78B	3.34B	3.13B	2.55B
Gross Profit	1.86B	1.38B	636.50M	1.66B	1.53B
EBITDA	338.69M	404.87M	678.69M	788.78M	881.27M
Net Income	211.24M	204.96M	413.17M	498.97M	567.19M
Balance Sheet
Total Assets	4.33B	2.87B	3.56B	2.77B	2.08B
Cash, Cash Equivalents and Short-Term Investments	655.28M	575.02M	553.14M	305.12M	338.51M
Total Debt	731.53M	304.79M	340.04M	300.01M	164.48M
Total Liabilities	1.51B	645.30M	929.04M	737.10M	533.08M
Stockholders Equity	2.82B	2.23B	2.63B	2.03B	1.54B
Cash Flow
Free Cash Flow	-949.49M	38.80M	-80.59M	-425.52M	101.42M
Operating Cash Flow	358.22M	352.86M	204.65M	138.25M	273.54M
Investing Cash Flow	-345.53M	-270.20M	-268.17M	-142.03M	-245.68M
Financing Cash Flow	-10.81M	-10.81M	-10.81M	-10.81M	-10.81M

NGL Fine-Chem Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1320.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NGLFINE, the sentiment is Negative. The current price of 1320.6 is above the 20-day moving average (MA) of 1293.28, above the 50-day MA of 1180.21, and below the 200-day MA of 1418.07, indicating a neutral trend. The MACD of 6.59 indicates Positive momentum. The RSI at 42.81 is Neutral, neither overbought nor oversold. The STOCH value of 13.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NGLFINE.

NGL Fine-Chem Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DMCC	74 Outperform	₹8.38B	30.03		0.30%	44.95%	184.04%
GANESHBE	69 Neutral	₹6.98B	17.58		―	-13.61%	-38.42%
INDOBORAX	67 Neutral	₹8.74B	22.60		0.38%	-8.39%	9.04%
NGLFINE	65 Neutral	₹8.27B	39.62		0.14%	6.44%	-50.37%
MANGALAM	58 Neutral	₹1.16B	19.78		―	-16.39%	-409.96%
Sector *	44 Neutral	C$923.76M	-8.68	-0.23%	2.69%	24.53%	-41.45%
SUKHJITS	―	₹5.25B	16.86		2.29%	―	―

NGL Fine-Chem Ltd. Corporate Events

NGL Fine-Chem Ltd. Announces Virtual AGM and E-Voting Details

NGL Fine-Chem Ltd. announced the details of its 44th Annual General Meeting (AGM), which will be held virtually on August 19, 2025. The company has provided electronic copies of the AGM notice and annual report to shareholders, emphasizing the use of remote e-voting for resolutions. This move reflects the company’s adaptation to digital processes, potentially enhancing shareholder engagement and operational efficiency.